Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
May 29, 2013 -- SFL is pleased to announce that Shayesteh Fürst-Ladani, SFL’s Managing Director, has been invited to give a presentation entitled “Early consideration of market access aspects – Impact on regulatory strategy” on 30 May 2013 at the Market Access Preliminary Skills for Regulatory Professionals event organized by the Regulatory Affairs Professionals Society (RAPS) Switzerland Chapter in Lausanne.
New evidence-based healthcare policies and budget controls are heightening interest in the emerging area of market access and health technology assessment (HTA). RAPS Switzerland has therefore been developing a Market Access Preliminary Skills for Regulatory Professionals’ Center of Excellence where participants can learn from industry specialists.
Shayesteh commented “I will outline the approach required to ensure that elements of common interest to both regulators and HTA bodies can be incorporated into companies’ clinical development plans.”
Shayesteh is the Managing Director and founder of SFL. She has comprehensive experience in formulating global regulatory strategies and provides support for the development of drugs, orphan drugs, drug and device combination products, borderline products, medical devices, in vitro diagnostics and advanced therapy medicinal products. Shayesteh is Chair of the Combination Products Topic Group at EuropaBio. She has been member of the Program Committee of DIA EuroMeeting for 2011, 2012, 2013 and 2014 leading the Theme Drugs, Devices, In Vitro Diagnostics and their Combinations. In 2012 she received the Open University Business School’s Alumni Award Outstanding Contribution to an Organization.
Help employers find you! Check out all the jobs and post your resume.
